文献速递胸部肿瘤

帕博利珠单抗联合培美曲塞铂类一线治疗转移性非鳞NSCLC的最终分析

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
PubMed 文献 · Ann Oncol · 2021-04-22

KEYNOTE-189 III期研究方案预设最终分析显示,中位随访31.0个月后,帕博利珠单抗联合培美曲塞铂类较安慰剂联合方案持续改善OS(HR 0.56;95%CI 0.46-0.69)和PFS(HR 0.49;95%CI 0.41-0.59),无论PD-L1表达状态。ORR为48.3%对19.9%,安全性可控。

要点

  • 帕博利珠单抗联合化疗持续改善OS和PFS,无论PD-L1表达。
  • ORR 48.3%对19.9%,PFS2 HR 0.50。
  • 56例完成35周期帕博利珠单抗,ORR 85.7%。

核心结论

  • 帕博利珠单抗联合培美曲塞铂类较安慰剂联合方案持续改善疗效结局,毒性可控。
  • 结果支持帕博利珠单抗联合培美曲塞铂类用于既往未治疗的转移性非鳞NSCLC一线治疗。

研究设计与样本

  • III期KEYNOTE-189研究(NCT02578680), eligible患者按2:1随机接受帕博利珠单抗200 mg(n=410)或安慰剂(n=206)每3周一次(最多35周期,约2年)联合4周期培美曲塞500 mg/m2及研究者选择的顺铂75 mg/m2或卡铂AUC 5 mg·min/ml每3周一次,后续培美曲塞维持至进展。
  • 安慰剂联合培美曲塞铂类组患者疾病进展后可符合条件交叉接受帕博利珠单抗。
  • 主要终点为OS和PFS。

主要发现

  • 中位随访31.0个月后,帕博利珠单抗联合培美曲塞铂类较安慰剂联合方案改善OS(HR 0.56;95%CI 0.46-0.69)。
  • PFS改善(HR 0.49;95%CI 0.41-0.59),无论PD-L1表达状态。
  • ORR为48.3%对19.9%。
  • PFS2改善(HR 0.50;95%CI 0.41-0.61)。

关键数值与推荐

  • 帕博利珠单抗联合培美曲塞铂类组3-5级不良事件发生率为72.1%,安慰剂联合培美曲塞铂类组为66.8%。
  • 56例患者完成35周期(约2年)帕博利珠单抗治疗,ORR为85.7%,截至数据截止时53例(94.6%)存活。

临床怎么用

  • 帕博利珠单抗联合培美曲塞铂类可作为既往未治疗的转移性非鳞NSCLC的一线治疗选择,无论PD-L1表达状态。
  • 治疗最多35周期(约2年),完成35周期者ORR达85.7%且绝大多数存活。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) versus placebo plus pemetrexed-platinum. We report updated efficacy outcomes from the protocol-specified final analysis, including outcomes in patients who crossed over to pembrolizumab from pemetrexed-platinum and in patients who completed 35 cycles (∼2 years) of pembrolizumab. PATIENTS AND METHODS: Eligible patients were randomized 2 : 1 to receive pembrolizumab 200 mg (n = 410) or placebo (n = 206) every 3 weeks (for up to 35 cycles, ∼2 years) plus four cycles of pemetrexed (500 mg/m2) and investigators' choice of cisplatin (75 mg/m2) or carboplatin (area under the curve 5 mg·min/ml) every 3 weeks, followed by pemetrexed until progression. Patients assigned to placebo plus pemetrexed-platinum could cross over to pembrolizumab upon progression if eligibility criteria were met. The primary endpoints were OS and PFS. RESULTS: After a median follow-up of 31.0 months, pembrolizumab plus pemetrexed-platinum continued to improve OS [hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.46-0.69] and PFS (HR, 0.49; 95% CI, 0.41-0.59) over placebo plus pemetrexed-platinum regardless of programmed death-ligand 1 expression. Objective response rate (ORR) (48.3% versus 19.9%) and time to second/subsequent tumor progression on next-line treatment (PFS2; HR, 0.50; 95% CI, 0.41-0.61) were improved in patients who received pembrolizumab plus pemetrexed-platinum. Eighty-four patients (40.8%) from the placebo plus pemetrexed-platinum group crossed over to pembrolizumab on-study. Grade 3-5 adverse events occurred in 72.1% of patients receiving pembrolizumab plus pemetrexed-platinum and 66.8% of patients receiving placebo plus pemetrexed-platinum. Fifty-six patients completed 35 cycles (∼2 years) of pembrolizumab; ORR was 85.7% and 53 (94.6%) were alive at data cut-off. CONCLUSIONS: Pembrolizumab plus pemetrexed-platinum continued to show improved efficacy outcomes compared with placebo plus pemetrexed-platinum, with manageable toxicity. These findings support first-line pembrolizumab plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous NSCLC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021. PMID: 33894335. doi:10.1016/j.annonc.2021.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。